TFS Capital’s Dare Bioscience DARE Stock Holding History

TFS Capital’s Portfolio DARE Stock Details DARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-132	Closed	-$43K	–	1004
2016 Q1	$43K	Buy	+132	New	+$37.2K	0.01%	958
2015 Q3	–	Sell	-864	Closed	-$477K	–	926
2015 Q2	$477K	Buy	864 +598	+225%	+$411K	0.05%	544
2015 Q1	$288K	Buy	+266	New	+$257K	0.03%	698

Other funds holding DARE

PVMCV

Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PVMCI

Polaris Venture Management Co IV Boston, Massachusetts $62.4M AUM 33.04% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

TFS Capital's DARE Position: Q2 2016 in Review

TFS Capital sold out of Dare Bioscience (DARE) in Q2 2016, closing a stake of 132 shares — an estimated $43K sold.

TFS Capital first reported a position in DARE in Q1 2015 and held it in 3 quarters. The position peaked at $477K in Q2 2015. 34 funds tracked by Wall St. Rank hold DARE as of Q2 2016.

TFS Capital reported no remaining Dare Bioscience position as of Q2 2016 after selling out during the quarter.
TFS Capital sold 132 Dare Bioscience shares in Q2 2016, an estimated $43K.
TFS Capital first reported a position in Dare Bioscience in Q1 2015 and held it in 3 quarters.
TFS Capital's Dare Bioscience position peaked at $477K in Q2 2015.
34 funds tracked by Wall St. Rank held Dare Bioscience as of Q2 2016.

Based on TFS Capital's 13F filing for Q2 2016, filed 11 Aug 2016.